Award
NIH Reporter #11261599
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Recipient
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Award Amount
$351,924.00
Ceiling
$351,924.00
Awarded
January 29, 2026
Identifier
11261599
NIH-funded research project at Icahn School of Medicine at Mount Sinai to enhance cancer immunotherapy through tumor-reactive T cell vaccination.
Description
This is a research project funded by the NIH National Cancer Institute, focusing on immunotherapy and cancer research. The project involves immunology studies, clinical trials, and advanced immune monitoring.